Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis
Shen H, Rodriguez AC, Shiani A, Lipka S, Shahzad G, Kumar A, Mustacchia P
Therapeutic advances in gastroenterology · 62 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Meta-analysis (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2015-07-20 · Ther Adv Gastroenterol · vol. 9 · issue 1 · pp. 113–120
- Publisher
- SAGE Publishing
- Cited
- 109 citations · more than 98% of similar papers · 7.5× the field average
- Impact
- Top 10% most cited in its field
- References
- 29 works
- Access
- Open access (repository copy)
- Research areas
- Coffee research and impacts · Liver Disease Diagnosis and Treatment · Tea Polyphenols and Effects
- Keywords
- Medicine, Caffeine, Nonalcoholic fatty liver disease, Internal medicine, Meta-analysis, Gastroenterology, Confidence interval, Fatty liver, Subgroup analysis, Cirrhosis, Fibrosis, Hepatic fibrosis, Disease
7 authors
From US
- Huafeng ShenNassau University Medical Center
- Andrea C. RodriguezUniversity of South Florida
- Ashok ShianiUniversity of South Florida
- Seth LipkaUniversity of South Florida
- Ghulamullah ShahzadNassau University Medical Center
- Ambuj KumarUniversity of South Florida
Abstract
Objectives
Caffeine consumption is reported to be associated with reduced hepatic fibrosis in patients with chronic liver diseases. We performed a systematic review and meta-analysis to assess the association between caffeine consumption and prevalence or hepatic fibrosis of nonalcoholic fatty liver disease (NAFLD) in observational studies.
Methods
We searched the literature of all languages from PubMed, EMBASE, and the Cochrane library from 1 January 1980 through 10 January 2015. Total caffeine consumption was defined as the daily intake of caffeine (mg/day) from all caffeine-containing products. Combined and subgroup analyses stratified by study designs, study locations, and type of caffeine intake were performed.
Results
Four cross-sectional and two case control studies with a total of 20,064 subjects were included in the meta-analysis. Among these, three studies with 18,990 subjects were included in the analysis for prevalence of NAFLD while the other three studies with 1074 subjects were for hepatic fibrosis. Total caffeine consumption (mg/day) was not significantly associated with either the prevalence [pooled mean difference (MD) 2.36; 95% confidence interval (CI) -35.92 to 40.64] or hepatic fibrosis (higher versus lower stages; pooled MD -39.95; 95% CI -132.72 to 52.82) of NAFLD. Subgroup analyses stratified by study designs and locations were also not significant. However, after stratifying by type of caffeine intake, regular coffee caffeine intake (mg/day) was significantly associated with reduced hepatic fibrosis of NAFLD (pooled MD -91.35; 95% CI -139.42 to -43.27; n = 2 studies).
Conclusion
Although total caffeine intake is not associated with the prevalence or hepatic fibrosis of NAFLD, regular coffee caffeine consumption may significantly reduce hepatic fibrosis in patients with NAFLD.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.